Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tigges

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Journal of Virology|November 16, 2012
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatmentDoug J Bartels, James C Sullivan, Eileen Z Zhang, et al.
Plos Computational Biology|August 8, 2014
Modeling viral evolutionary dynamics after telaprevir-based treatmentEric L Haseltine, Sandra De Meyer, Inge Dierynck, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2007
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine proteaseYi Zhou, Doug J Bartels, Brian L Hanzelka, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trialsJames C Sullivan, Sandra De Meyer, Doug J Bartels, et al.
Frontiers in Education|December 17, 2024
An inclusive Research Education Community (iREC) Model to Facilitate Undergraduate Science Education ReformDenise L Monti, Julia C Gill, Tamarah L Adair, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Journal of Virology|November 16, 2012
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatmentDoug J Bartels, James C Sullivan, Eileen Z Zhang, et al.
Plos Computational Biology|August 8, 2014
Modeling viral evolutionary dynamics after telaprevir-based treatmentEric L Haseltine, Sandra De Meyer, Inge Dierynck, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2007
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine proteaseYi Zhou, Doug J Bartels, Brian L Hanzelka, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trialsJames C Sullivan, Sandra De Meyer, Doug J Bartels, et al.
Frontiers in Education|December 17, 2024
An inclusive Research Education Community (iREC) Model to Facilitate Undergraduate Science Education ReformDenise L Monti, Julia C Gill, Tamarah L Adair, et al.
Pageof 9